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Abstract
The placenta is considered an important organ that evolves with the implantation of the 
blastocyst throughout the pregnancy. The placenta has an essential role in functions such 
as nutrition, excretion, and immunologic and endocrine function. The normal placenta 
is a round- or oval-shaped organ that attaches to the uterine wall and has roughly 22 cm 
in diameter and a thickness of about 2–2.5 cm and weighs about one sixth of the fetal 
birth weight. Thus, a normal development of the placenta is important for an uneventful 
embryonic and fetal development. Consequently, the placenta abnormalities can range 
from structural anomalies, to function disorders, to site of implantation abnormalities.
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1. Introduction
The placenta is a crucial feto-maternal organ with both embryonic (chorion frondosum) and 
maternal (decidua basalis) components. The development of the placenta begins with the 
implantation of the blastocyst into the maternal uterus, and it evolves throughout the preg-
nancy. At the end of the first trimester of pregnancy, the maternal blood supply to the placenta 
is complete. The placenta has numerous and complex, developmentally essential functions 
such as nutrition, excretion, and immunologic and endocrine function. The normal placenta 
is a round- or oval-shaped organ that attaches to the uterine wall and has roughly 22 cm in 
diameter. The placenta thickness is about 2–2.5 cm and weighs about one sixth of the fetal 
birth weight [1]. Thus, a normal development of the placenta is important for an uneventful 
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embryonic and fetal development. Consequently, the placenta abnormalities can range from 
structural anomalies, to function disorders, to site of implantation abnormalities [1].
2. Placenta accreta, placenta increta, and placenta percreta
Abnormal placental implantation (accreta, incretak, and percreta) is described using a gen-
eral clinical term, respectively, morbidly adherent placenta (MAP) [2] or “abnormal invasive 
placenta” (AIP). If not diagnosed before delivery, MAP can lead to catastrophic postpartum 
hemorrhage, with life-threatening complications. Risk factors include increased maternal age, 
previous Cesarean delivery or myomectomy, multiparity, and previous intrauterine maneuvers 
(such as hysteroscopy and multiple dilatation and curettage [3]). The reported incidence ranges 
from 1:2500–1:7000 pregnancy in 2007 [4] to 1:533 deliveries in 2017 [3]. When the placental 
villi attach to the myometrium rather than the decidua, it is called placenta accreta; when the 
chorionic villi penetrate the myometrium, it is called placenta increta (e.g., Figure 1), whereas 
placenta percreta extends into the uterine serosa or adjacent organs (e.g., Figure 2). Placenta 
increta and placenta percreta are rare disorders, which represent <20% of the cases of placenta 
accreta [5]. These varieties can lead to more severe maternal complications (60% maternal mor-
bidity [6], 7–10% maternal mortality [7]). The most important measure in decreasing these 
potentially fatal complications is the prenatal ultrasound diagnosis. In many cases, the patient’s 
history is highly relevant. The key feature for early first-trimester diagnosis of MAP is an abnor-
mal neovascularization in the ill-defined placental-myometrial junction detected in a color or 
power Doppler (2D or 3D) image [8], similar to the flow observed in an invasive mole, arterio-
venous malformation, or retained products of conception. Other aspects can include focal or dif-
fuse irregular lacunar lakes with turbulent flow typified by a high velocity (PSV, >15 cm/s) [9]. 
A higher number of lakes increase the risk of a presenting placenta accreta. The complete loss 
or disruption of the echolucent myometrial zone between the placenta and bladder is highly 
suggestive for MAP. When using color Doppler examination, the sensitivity and specificity of 
Figure 1. Ultrasound color Doppler image of a case of placenta increta diagnosed in the early second trimester of 
pregnancy, associated with fetal demise. The surgical termination of pregnancy was performed under laparoscopic 
guidance, with no complications.
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the ultrasound scan can be as high as 80–90% and, respectively, 98% [10]. Magnetic resonance 
imaging can add accuracy to MAP diagnosis when assessing the lateral extension and penetra-
tion depth of the placenta. However, a majority of cases of MAP are diagnosed during the third 
stage of labor or during Cesarean section [9], and about 21% of cases of MAP are responsible 
for peripartum hysterectomy [11]. Overall, in suspected cases with this type of placental pathol-
ogy, the best approach includes a multidisciplinary team with early planning for antepartum 
and intrapartum management, preferable than late planning [12]. Some groups recommend 
delivery at 34–35 weeks by performing preterm Cesarean section with the placenta left in situ 
[13]. Other several adjuvant techniques have been proposed, as methotrexate treatment and/or 
placement of internal iliac artery balloon catheters, for occlusion and/or arterial embolization 
[14]. The goal of the conservative approach of MAP is the attempt of gradual resorption of the 
placenta or delayed delivery of the placenta [15]. A good prognosis of MAP pathology is fea-
sible, with improving maternal and fetal outcome, if diagnosis is timely and there is adequate 
preparation of the delivery. These are essential keys in the management of such cases [16].
3. Placenta praevia
This type of obstetric pathology was firstly described in 1685 by Paul Portal, a French physician 
[17], as a major cause of hemorrhage, with a potentially life threat to the mother and the fetus. It 
was defined as the placenta that overlies entirely or partially the internal cervical os of the uterus. 
In complete praevia, the internal os is completely covered by the placenta (e.g., Figure 3). Placenta 
praevia is divided into partial praevia (a portion of the internal os is covered by the placenta), 
Figure 2. Image of the uterus occupied by placenta percreta after postpartum hysterectomy due to important hemorrhagic 
complications.
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marginal praevia or praevia maginalis (the edge of the placenta extends to the edge of the cervical 
os), and low-lying placenta defined as within 2 cm of the cervical os, without covering it [2]. The 
reported incidence of the condition is 1 in 200–250 pregnancies [1]. Among the risk factors, there 
are prior Caesarean delivery, previous abortion, prior intrauterine surgery, smoking, multife-
tal gestation, increase in parity, and increased maternal age. The risk for placenta praevia is 12 
times higher in women with history of placenta praevia in a previous pregnancy. Some studies 
demonstrated an increased rate of placental insufficiency in women with placenta praevia [18]. 
However, in a retrospective study of women with a complete or partial praevia, no fetal growth 
restriction was diagnosed [19]. The placenta location must be recorded during the ultrasound 
scan in the first- and early second-trimester pregnancies. If the placenta is significantly low, an 
additional ultrasound scan at the beginning of the third trimester allows the final diagnosis. 
Patients should be aware that nothing can be done to prevent placenta praevia. The appropriate 
delivery in placenta praevia is by Cesarean section, as dilation of the cervix causes separation of 
the placenta, leading to bleeding from the opened vessels. Still, in cases of a low-lying placenta, as 
the bleeding morbidity has proven to be limited, a vaginal delivery remains an option [1]. Every 
hospital must have a suitable protocol or algorithm for the management of placenta praevia, as 
this is a condition with high maternal and fetal morbidity and mortality [20].
4. Vasa praevia
Vasa praevia is a rare condition, in which the fetal blood vessels traverse the lower uterine seg-
ment in advance of the presenting part, unsupported by either the umbilical cord or placental 
tissue (e.g., Figure 4). This pathologic structure can cause fetal blood loss, with significant neona-
tal morbidity or death in case of spontaneous rupture of membranes or amniotomy. Also, fetal 
heart decelerations and bradycardia can occur if compression of these vessels appears, due to the 
presenting part [20]. This condition is encountered in 1:2500–5000 pregnancies [21]. The prenatal 
diagnosis is made with a high accuracy by ultrasound, with a sensitivity of 100% and a specificity 
Figure 3. Ultrasound image of complete placenta praevia percreta in a patient with a previous Cesarean section (color 
Doppler examination showing the penetration of the placenta into the bladder).
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of 99–99.8%, if transvaginal color Doppler examination is used [20]. If unrecognized before the 
onset of labor, the fetal mortality rate ranges between 22.5 and 100% [22]. To improve the prenatal 
diagnosis, the prenatal ultrasound form should include a standard evaluation of the umbilical 
cord insertion site. However, some researchers demonstrated that general screening for vasa prae-
via is not cost-effective and is not advised [23]. There are recent reports of two main associations: 
velamentous insertions and vessels crossing between lobes in succenturiate or bilobate placentas 
[24]. Besides these strong risk factors, others include placenta praevia and conception by assisted 
reproductive technologies. If diagnosed with vasa praevia, elective Cesarean delivery should be 
proposed at 35–36 weeks [25]. Others prefer a scheduled Cesarean section at 37–38 weeks or when 
fetal lung maturation has been confirmed [26, 27]. The Canadian guidelines for the management 
of prenatally diagnosed vasa praevia include elective Cesarean section prior to the onset of labor. 
Also, as premature delivery is most likely, consideration should be given to administration of 
corticosteroids at 28–32 weeks (to promote fetal lung maturation), and hospitalization at about 
30–32 weeks is advisable. Continuous electronic fetal heart rate monitoring and a rapid biochemi-
cal test for fetal hemoglobin can be considered, and if any of the above tests are abnormal, emer-
gency Cesarean section should be performed [28]. Overall, physicians must be vigilant whenever 
amniotomy is performed as not all cases of vasa praevia are diagnosed antenatally. Any case of 
suspicion should benefit of immediate delivery, to avoid fetal shock or demise [22].
5. Placenta variants
5.1. Bilobed placenta
Bilobed placenta (placenta bilobate, bipartite placenta, placenta duplex) is a placental morpho-
logical anomaly that refers to a placenta separated into two roughly equal-sized lobes, separated 
by membranes (e.g., Figure 5). If there are more than two lobes, then the placenta is called a mul-
tilobed placenta. The estimated incidence is 2–8% of placentas [29]. The pathology of this type of 
placenta is considered to be a result of a localized placental atrophy, as a result of poor decidu-
alization or vascularization of a part of the uterus (dynamic placentation theory) [30]. Also, the 
Figure 4. Ultrasound color Doppler image showing vasa praevia.
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genetic origin has been considered, as the risk of a bipartite placenta is greater in a woman with 
already a history of bipartite placenta. Frequent association with a velamentous insertion of the 
cord is reported, as the umbilical cord may insert in either lobe or in between the lobes. The diag-
nosis of bilobed placenta is made by ultrasound assessment when two separate placental discs of 
nearly equal size are noted. In cases of bilobed placenta, there is no increased risk of fetal anoma-
lies. However, this type of placental abnormality can be associated with first-trimester bleeding, 
polyhydramnios, abruption, and retained placenta. Also, it can increase the incidence of vasa 
praevia with a high incidence of hemorrhage. Taking all these risk factors into consideration, a 
bilobed placenta does not have any unfavorable short-term or long-term pregnancy outcomes.
5.2. Circumvallate placenta
Circumvallate placenta represents one type of an extrachorial placenta, defined as an annularly 
shaped placenta with raised edges composed of a double fold of chorion, amnion, degenerated 
decidua, and fibrin deposits [1]. Pathologically, the basal plate is larger than the chorion fron-
dosum [31]. The incidence of circumvallate placenta has been reported in 0.5–18% of placentae 
examined after delivery [32, 33]. There is an increased risk of vaginal bleeding at the beginning 
of the first trimester and also a risk of premature rupture of the membranes, preterm deliv-
ery, placental insufficiency, and placental abruption [34, 35]. The pregnancy outcome can be 
very poor. Prenatally, during the ultrasound scan, circumvallate placenta can be suspected as a 
peripheral rim of chorionic tissue appearing as an echodense ridge (placental shelf), with a “tire 
sign” appearance on the 3D exam [36]. However, the diagnosis is made most often after delivery, 
by inspection of the placenta. If circumvallate placenta is suspected antenatally, the pregnancy 
should be classified as a high-risk pregnancy, and special precautions should be considered, to 
prevent preterm labor. A high association between circumvallate placenta and a single umbilical 
artery [37] and no relationship between the amniotic band syndrome or limb body wall complex 
and circumvallate placenta have been reported [31]. Thus, the condition carries no risk of fetal 
deformity. Circummarginate placenta is another type of extrachorial placenta, with no clinical 
significance, where the transition from membranous to villous chorion is flat [1].
Figure 5. Ultrasound image (gray scale and color Doppler) of a bilobed placenta, showing the two lobes of the placenta 
and the umbilical cord insertion in one of the lobes.
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5.3. Placenta membranacea
Placenta membranacea is an extremely uncommon variation in placental morphology, in which 
the placenta develops as a thin structure, occupying the entire periphery of the chorion. This 
type of placental abnormality is classified as diffuse placenta membranacea (with chorionic villi 
covering the fetal membranes completely) and partial placenta membranacea [1]. The estimated 
incidence is 1:20,000–1:40,000 pregnancies [38], with an association of abnormal placental adher-
ence in up to 30% of cases [38]. The ultrasound assessment is useful, but being an extremely rare 
variant, there are no reports of its sensibility and specificity. The common symptom of this type 
of placental pathology is vaginal bleeding in the second or third trimester (often painless) or 
during labor. Complications such as antepartum hemorrhage, second-trimester miscarriages, 
fetal demise, and postpartum hemorrhage have been reported in pregnancy with placenta 
membranacea [39]. Placenta praevia and placenta accrete or intrauterine growth restriction can 
also be associated with this condition, worsening the maternal and fetal prognosis [30, 40].
5.4. Succenturiate placenta
In succenturiate placenta a smaller accessory placental lobe develops in the membranes, 
apart from the main disc of the placenta. There can be more than one succenturiate lobe, and 
it is a smaller variant of a bilobed placenta. In placenta supuria the communicating mem-
branes do not have vessels [1]. As risk factors, advanced maternal age, in vitro fertilization, 
primiparity, proteinuria in the first trimester of pregnancy, and implantation over leiomyo-
mas or in areas of previous surgery have been cited in the literature [1]. This condition can 
be diagnosed in 5% of pregnancies, by ultrasound scan as a smaller separate lobe similar to 
the main placental lobe. Caution should be considered in identifying any connecting ves-
sels, especially vasa praevia. Differential diagnosis may also include focal myometrial con-
traction and iso-echoic hematoma from a placental abruption. Complications may appear 
as there is an increased risk of vasa praevia and postpartum hemorrhage, due to retained 
placental tissue.
6. Chronic intervillositis
Chronic intervillositis, also known as massive chronic intervillositis or chronic histiocytic 
intervillositis, is an exceptionally rare placental anomaly, defined by inflammatory placental 
lesions [1], mainly diffuse histiocytic infiltrate in intervillous space [41]. Among risk factors, 
maternal diabetes, maternal hypertension, intravenous drug abuse, preeclampsia, and sys-
temic lupus erythematosus are mentioned. This condition has a perinatal mortality of 80%, 
due to an associated risk of recurrent spontaneous abortion [42], fetal growth restriction [43], 
and fetal death. The recurrence rate is considered to be above 60%.
7. Placental mesenchymal dysplasia
Placental mesenchymal dysplasia is a rare vascular anomaly of the placenta characterized by 
mesenchymal stem villous hyperplasia [1]. The ultrasound diagnosis includes placentomegaly 
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Figure 6. Ultrasound color Doppler image of a chorioangioma diagnosed in the second trimester of pregnancy.
and a “grape-like” placental appearance, both mistaken clinically and macroscopically for a 
partial hydatidiform molar pregnancy [44]. The differential diagnosis is important, because 
it may result in termination of pregnancy. Still, the final diagnosis is made by means of pla-
cental histology. The disorder also has been reported to be associated with both intrauterine 
growth restriction (IUGR) and fetal death [45]. In many cases, the cause of fetal death is fetal 
vascular obstructive pathology, causing longstanding, severe fetal hypoxia, due to chorionic 
vessel thrombosis [46]. Beckwith-Wiedemann syndrome has been linked to placental mesen-
chymal dysplasia. Invasive testing is advisable to confirm a normal karyotype and exclude 
partial molar pregnancy [47].
8. Diabetic placenta
The placenta represents a natural selective barrier between maternal and fetal blood circula-
tions, and it is highly sensitive to the hyperglycemic environment. Consequently, adaptive 
changes of the structure and function appear. The histological findings are typical: villous 
immaturity, villous fibrinoid necrosis, chorioangiosis, and increased angiogenesis [48]. Chronic 
fetal hypoxia can occur due to placental changes associated with inflammation and oxidative 
stress. Potential intrauterine complications are growth restriction, premature labor, preeclamp-
sia, risk of oxygen deprivation, low neonate body temperature, low blood sugar levels at birth, 
and stillbirth [49].
9. Placental chorioangioma
Chorioangioma is a benign vascular tumor, found in approximately 1% of all pregnancies [50]. 
It was firstly described in 1798 by Clarke [51]. This pathology is a malformation of the primi-
tive angioblastic tissue of the placenta perfused by the fetal circulation. It is rarely clinically 
significant and is usually discovered incidentally. Most of the chorioangiomas have small 
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dimensions. However, large chorioangiomas have been associated with a range of fetal 
conditions (fetal anemia, thrombocytopenia, hydrops, hydramnios, intrauterine growth 
retardation), including prematurity and stillbirth [1]. Also, large tumors can degenerate in 
necrosis, calcification, hyalinization, or myxomatous degeneration. Typically, on the ultra-
sound, a chorioangioma is located near the insertion of the cord into the amniotic cavity, as a 
hypoechoic, rounded mass with usually anechoic cystic areas with low resistance pulsatile flow 
(e.g., Figure 6) [52]. In rare cases the tumors are pedunculated. As differential diagnosis, 
subamniotic hematoma, partial hydatidiform mole, submucosal uterine fibroid, placenta tera-
toma, and atypical placental venous lake should be considered [53].
10. Placental infections
Most infections arise from several infective agents that may cross into the placenta from the 
maternal circulation [1]. These kinds of infections can be associated with a variety of devel-
opmental effects, from virtually insignificant to major maternal and fetal developmental 
complications. Placental examination by a pathologist should be considered in every case of 
preterm delivery, fetal tachycardia, maternal signs of endomyometritis (e.g., fever, uterine 
tenderness, leukocytosis, tachycardia), neonatal intensive care unit admission, malodorous 
placenta, retained placenta or postpartum hemorrhage, and stillbirth [54]. However, a 
specific infectious agent is rarely diagnosed by placental examination. Still, the placen-
tal histology may confirm the clinical diagnosis of an infectious etiology in some cases of 
nonreassuring fetal heart rate patterns or neonatal morbidity/mortality. The most common 
placental infections are:
• Malaria: characterized by the pigment-laden maternal red blood cells and macrophages 
aggregate in the intervillous space [55].
• Cytomegalovirus is the most common congenital viral infection, mostly subclinical at birth 
in cases of intrauterine growth restriction and stillbirths [56]. The classic histopathological 
finding in the placenta includes viral inclusions. These may be detected only if using im-
munohistochemistry techniques.
• Herpes simplex virus: the histopathological features of the placenta may include lym-
phoplasmacytic villitis. The demonstration of the virus by immunohistochemistry or by 
molecular techniques allows the diagnosis, since the above findings are nonspecific [57].
• Listeria monocytogenes is characterized by acute villitis, with abscess formation and fetal 
central nervous system damage [58].
• Streptococcal infection: both group B and group A streptococci can produce placental 
infection.
• Syphilis: Treponema pallidum infections determine a chronic villitis (plasma cells, mixed 
acute and chronic infiltrate).
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• Toxoplasmosis implies a risk of placental colonization, depending on the volume of 
uteroplacental blood flow, on the maternal immunocompetence, and parasitemia. Pla-
cental infection, described by granulomatous villitis, cysts, plasma cell deciduitis, villous 
sclerosis, and chorionic vascular thrombosis, is more common with advancing gestational 
age at the time of maternal parasitemia [59].
• Chlamydia psittaci: can infect the placenta and can cause significant feto-maternal morbidity 
and mortality by an intense, acute intervillositis, perivillous fibrin deposition with villous 
necrosis, and large irregular basophilic intracytoplasmic inclusions within the syncytiotro-
phoblast [60, 61].
11. Placental membranes
The fetal membranes (chorion, amnion) represent the interface between the fetal graft and 
the maternal host [1]. Infection may also pass the fetal membranes, especially in the area 
overlying the cervix. It provides direct access to pathogens, ascending from the vagina and 
the cervix [62]. Less commonly, infectious agents enter the uterus as a result of invasive pro-
cedures (e.g., amniocentesis, fetoscopy, cordocentesis, and chorionic villus sampling) or via 
the fallopian tubes from an infectious process in the peritoneal cavity.
11.1. Chorioamnionitis
Chorioamnionitis is the most frequent histopathological result of ascending transcervical 
infection and occurs with both symptomatic and silent infections [63]. The histologic diag-
nosis of chorioamnionitis is allowed if the inflammatory infiltrate involves either or both the 
chorion and the amnion. The acute chorioamnionitis is more common than the chronic form 
[64]. As clinical symptoms, chorioamnionitis is characterized by maternal fever, tachycardia, 
uterine tenderness, or foul-smelling amniotic fluid. However, cultures of the amniotic fluid 
or membranes fail to document the bacterial infection in 25–30% of placentas with histologic 
chorioamnionitis [65]. The infection of the membranes is often polymicrobial, with the most 
commonly seen bacteria: Streptococcus sp., Escherichia coli, Ureaplasma sp., Fusobacterium sp., 
Mycoplasma sp., and anaerobes [63]. The correct diagnosis and treatment of chorioamnionitis 
are paramount, as it is an important cause of perinatal and maternal morbidity and mortality 
[66]. The major pathological consequences of chorioamnionitis may include premature rup-
ture of membranes, preterm labor, prolonged labor, premature delivery, fetal and newborn 
infection, and endomyometritis.
12. Gestational trophoblastic disease.
12.1. Hydatidiform mole
Hydatidiform mole (HM), called also a molar pregnancy, represents a subcategory of gesta-
tional trophoblastic disease. The origin of the entity is the gestational tissue. The character 
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of HM is usually benign, but it has a known potential to become malignant and invasive. 
The incidence of a HM is 1:1000–2000 [67]. Risk factors include extremes of maternal age 
(greater than 35 years old and less than 20 years old), a previous molar pregnancy, women 
with previous spontaneous abortions or infertility, dietary factors, and smoking [68]. The 
HM can be a complete mole, with the absence of the fetus, or a partial mole with an abnormal 
fetus or a fetal demise; rarely, a mole coexists with a normal pregnancy. In complete HM, 
90% of cases the karyotype are 46XX diploid, while in partial HM, the karyotype is usu-
ally triploid 69XX [1]. The histopathological event of HM is considered to be a prolifera-
tion of the villous trophoblast, accompanied by swelling of the chorionic villi, resulting 
in high levels of human chorionic gonadotrophin (hCG) production (e.g., Figure 7) [68]. 
The location of the HM is the uterine cavity, with exceptionally rare cases located in the 
fallopian tubes or ovaries. Clinically, the most common symptom is the vaginal bleed-
ing in the first trimester. Sometimes an association of hyperemesis (severe nausea and 
vomiting) or passage of vaginal tissue described as “grape-like clusters” or “vesicles” can 
be encountered. If not early diagnosed, other significant complications may appear, such 
as hyperthyroidism, including tachycardia and tremors and preeclampsia. Usually, on a 
physical exam, there is a uterine size discrepancy compared with the amenorrhea period, 
the uterus being larger in complete mole and smaller in partial mole [69]. The ultrasound 
exam finding is a heterogeneous mass in the uterine cavity, with multiple anechoic spaces 
Figure 7. Image of post-hysterectomy uterus invaded by a hydatidiform mole in a 48-year-old patient.
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(e.g., Figure 8). The “snow storm” or “bunch of grapes” appearance is no longer seen with 
nowadays equipment. In complete moles the embryo is absent, and no amniotic fluid is 
present [70]. In the first trimester, the diagnosis of complete mole can be difficult; bilateral 
theca lutein cyst may be seen [71]. In partial mole, the molar placenta may not always be 
seen; the amniotic cavity is either empty or contains a well-formed but growth-retarded 
fetus, either dead or alive, with hydropic degeneration of fetal parts [72]. Occasionally, 
the differential diagnosis between partial moles, complete moles, and missed abortion [73] 
may be difficult. In molar pregnancy the first step after the diagnosis is the chest X-ray to 
determine metastasis. Computer tomography and magnetic resonance imaging can add 
valuable additional information for the final diagnosis. After careful counseling of the 
patient, including genetic testing, the best treatment option remains suction and curet-
tage for evacuation. Hysterectomy, however, is an option if preservation of the fertility is 
not necessary. When hCG levels remain elevated after a proper evacuation of the uterine 
cavity, a gynecology oncology consultation is required to guide the therapy and consider 
chemotherapy [68].
12.2. Choriocarcinoma
Choriocarcinoma is a rare aggressive tumor, with highly malignant potential and widespread 
dissemination metastases [74]. It is considered part of the spectrum of gestational trophoblastic 
disease and is called gestational choriocarcinoma. The high mortality is due to lack of early 
diagnosis and appropriate chemotherapy [75]. Approximately 5% of cases of complete HM 
can be complicated with choriocarcinoma. Only about half the cases of choriocarcinoma 
arise from a complete HM. The imaging diagnosis of choriocarcinoma includes a discrete, 
central, infiltrative mass enlarging the uterus, with a possible invasion of the myometrium 
and beyond (e.g., Figures 9 and 10). The ovaries may be enlarged, due to cysts secondary to 
increased levels of hCG [76]. If choriocarcinoma arises from a complete HM, the prognosis is 
usually favorable after proper chemotherapy. On the contrary, other cases of choriocarcinoma 
have a less favorable prognosis.
Figure 8. Ultrasound image of the case of hydatidiform mole.
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Figure 9. Ultrasound image in gray and color Doppler scale showing a rare case of choriocarcinoma of the cervix with 
intense vascularization.
Figure 10. Ultrasound image in gray and color Doppler scale showing a case of choriocarcinoma with invasion of the 
myometrium and beyond.
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